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Five years into the human postgenomic era, we are gaining considerable knowledge about 
host-pathogen interactions through host genomes. This “infectogenomics” approach 
should yield further insights into both diagnostic and therapeutic advances, as well as 
normal cellular function.As with most biological phenom-
ena, disease is the outcome of both 
nature and nurture. In the case of 
infectious disease, however, the 
interaction of two natures, that is, 
two genomes (host and pathogen), 
is at play. Environmental and social 
factors, or nurture, may affect the 
risk of acquiring infection, and also 
the risk of becoming ill. How we 
behave and what environment we 
live in will determine the number of 
exposure events (Weiss and McMi-
chael, 2004). The dose of infection 
and the fitness of the host and path-
ogen will determine sickness (van 
Opijnen and Berkhout, 2005). After 
all, unfit pathogens can make excel-
lent live attenuated vaccines.
The inherent virulence of the patho-
gen should always be considered in 
the setting of the host. This interplay 
is particularly evident in cross-spe-
cies infections. Herpes B virus elic-
its little more than cold sores in its 
natural host, the macaque, whereas 
in humans it causes a life-threatening 
encephalitis. Similarly, Escherichia coli 
O157 rarely affects cattle adversely 
but gives humans severe diarrhea, 
and H5N1 avian influenza virus is 
more virulent in geese, chickens, and 
humans than in ducks. Many host-
microbe combinations coevolve with 
an apparent drive toward decreased 
pathogenicity of the microbe in its 
host reservoir, a constraint that can be 
relieved upon transfer of the microbe 
to another species.
In studying the severity of infec-
tious diseases, it is not always clear how much variation to attribute to 
the virulence of the pathogen and 
how much to the susceptibility of 
the host. In some situations, how-
ever, the pathogen can be regarded 
as a constant, thereby revealing 
the contribution of the host. For 
instance, the SARS coronavirus that 
spread from human to human dur-
ing the 2003 outbreak came from a 
point source and was essentially an 
invariant clone. Yet we can discern at 
least three human host phenotypes 
of infection, namely, death, recov-
ery, and superspreaders. Moreover, 
being a superspreader was not highly 
correlated with severity of disease, 
and luckily for the human population, 
superspreaders represented a small 
proportion of those who became 
infected. We do not know to what 
extent human genetic variation deter-
mined death, recovery, and infec-
tiousness to others, but it should be 
studied. Doubtless, correlations will 
be found in the immunogenetics of 
the major histocompatibility complex 
(MHC). However, other factors that 
are difficult to reduce to one type of 
gene—possibly specific differences 
in the coordinated multicell, multi-
pathway response to SARS corona-
virus—may have been involved.
Similarly, the contribution of path-
ogen variation to pathogenesis is 
complex. Recent clues suggest a 
functional consequence of RNA virus 
variation that results from error-prone 
viral RNA polymerases producing 
genetically distinct but related viral 
“quasispecies.” For poliovirus, the Cell 124, Fequasispecies itself, rather than the 
presence of individual adaptive muta-
tions, resulted in increased patho-
genesis, supporting the theory that 
viral colonization of an ecosystem (in 
this case the host) may be a result 
of the complex interplay between dif-
ferent members of the quasispecies 
(Vignuzzi et al., 2006).
How Pathogens Have Shaped 
Our Genotype
It is generally agreed that common 
genetic polymorphisms, such as those 
in the ABO blood groups and MHC 
antigens, are maintained in human 
populations on account of their value 
in the immune response to infectious 
diseases. However, clear examples of 
balanced polymorphisms are few, and 
we have to beware of altruistic inter-
pretations. Perhaps the best evidence 
is where there is a tradeoff between 
resistance to infection and genetic dis-
ease. This is seen in the various hemo-
globinopathies (α- and β-thalassemia, 
and sickle cell anemia) where the 
resistance to infection with the malaria 
parasite of those who are hetero-
zygous for the gene mutation counter-
balances the lethal effects of recessive 
disease in homozygotes. The relatively 
high frequency of cystic fibrosis may 
also be explained if those hetero-
zygous for mutations in the chloride 
channel (CTFR) survive severe enteric 
infections such as typhoid because 
of reduced dehydration; in this case, 
heterozgotes may be considered the 
functional equivalent of oral rehydra-
tion therapy.bruary 24, 2006 ©2006 Elsevier Inc. 695
There are also examples of host 
genetic resistance to infections in 
which the homozygous state is not 
lethal. The delta 32 deletion in the 
gene encoding the CCR5 chemokine 
receptor is frequent in the Caucasian 
population. Homozygotes appear to 
be healthy and are resistant to infec-
tion by the majority of strains of HIV-1 
that require this receptor to enter their 
target cells. Heterozygotes also ben-
efit from relative resistance to infec-
tion and, when infected, progress to 
AIDS more slowly. But like cholera 
and CTFR, HIV is too recent an arrival 
in humans to account for the selec-
tion of delta 32 CCR5. Resistance 
to smallpox or the plague has been 
postulated as the original selective 
force, but compelling evidence has 
not been forthcoming.
Host Variation in Infectious 
Disease
The occurrence of these classical 
Mendelian traits that have large dis-
crete effects suggests that searching 
the human genome will reveal poly-
morphisms that affect susceptibility 
to specific infectious diseases. To 
date, however, scanning the genome 
for single-nucleotide polymorphisms 
(SNPs) or other markers has not 
been particularly fruitful in revealing 
genetic loci associated with a trait 
for infectious diseases. This is due to 
the fact that much of the genetic vari-
ation underlying infectious disease 
susceptibility is complex, involving 
the combination of many loci, and 
is further confounded by SNP varia-
tions between different populations 
and ethnic groups. Such surveys, 
therefore, require careful design, and 
it may be that identifying loci in ani-
mal models is a more straightforward 
way of highlighting loci and genes 
in humans. Correspondingly, it has 
been more fruitful thus far to identify 
polymorphisms in candidate human 
genes for infectious disease.
Multigenic Variation: HIV and AIDS
Both HIV infection and progression to 
AIDS are influenced by the host gen-
otype, and in turn, the host imposes 
selection on the virus. Obvious can-
didate genes have been investigated 696 Cell 124, February 24, 2006 ©2006 Ein HIV pathogenesis. As expected, 
both class I and class II genes in the 
MHC region affect HIV susceptibility 
and disease progression (Carrington 
and O’Brien, 2003), but it is the com-
bination of “good” and “bad” alleles 
that determines the phenotype of the 
disease. There is even a suggestion 
that rare MHC alleles offer stronger 
cellular immune responses to HIV 
because the viral peptide sequences 
have mutated to evade the more 
common MHC genotypes (Scherer 
et al., 2004).
An excellent example of multigenic 
variation in AIDS is the complexity 
of host receptor-ligand interactions. 
Most of the transmissible strains of 
HIV-1 require the CCR5 chemokine 
receptor as a fusion receptor after 
the virus particles bind to the CD4 
receptor on host T cells. There are 
widespread polymorphisms in the 
promoter region of the CCR5 gene 
that affect the density of receptor 
expression on the surface of CD4+ T 
lymphocytes. There is also polymor-
phism in the number of gene copies 
of its main ligand, the CCL3L1 form of 
the cytokine MIP-1α. Careful analysis 
of susceptibility to HIV infection and 
progression to AIDS in large human 
cohorts reveals that it is the combina-
tion of CCR5 and CCL3L1 polymor-
phisms that has the most telling effect 
on disease (Gonzalez et al., 2005). 
High chemokine expression com-
bined with low receptor expression 
delays the development of AIDS in 
the host. This makes sense from our 
understanding of HIV entry into cells 
because CCL3L1 competes with HIV 
for a limiting number of receptors.
Intracellular host restriction fac-
tors, such as APOBECG3 and 
Trim5α, also affect HIV infection. 
Polymorphisms in these proteins 
have been analyzed principally by 
comparison of host species. The 
virus had to develop mutations in the 
proteins that interact with these host 
factors to adapt to its new human 
host. However, recent data indicate 
that polymorphisms within human 
populations may also play a role in 
susceptibility to HIV (An et al., 2004; 
Sawyer et al., 2006) and routes of 
infection (Shrestha et al., 2006).lsevier Inc.Host Genetics of Common 
Infections
Regarding common infections 
that are seldom pathogenic, we 
can envisage an infectogenomics 
approach analagous to pharmacoge-
netics. The appearance of a disease 
or symptom following exposure to an 
infectious agent can be regarded as 
an unusual “side effect” just like an 
adverse reaction to a drug.
With the wrong genotype, such 
adverse reactions can be severe 
indeed. For example, 85% of the glo-
bal human population, or approxi-
mately 5 billion people, are persist-
ently infected with Epstein-Barr virus 
(EBV). Most of us become infected 
in infancy without diagnosed illness, 
although infection in adolescence 
causes infectious mononucleosis. 
But if an infant is homozyogous for 
the Duncan’s syndrome allele, pri-
mary infection leads to uncontrol-
lable, lethal mononucleosis. Curi-
ously, this gene appears to affect the 
response to EBV exclusively; it is not 
related to a more general immune 
deficiency.
Other infections may exhibit mild 
symptoms, except in rare cases of 
severity, such as those caused by 
cytomegalovirus (CMV) or human 
herpes virus type 6 (also see the 
Essay by S. Falkow, page 699 of this 
issue). The throat infection, Neis-
seria meningococcus, circulates 
among asymptomatic carriers but 
causes meningitis on rare occa-
sions. Perhaps we should not only 
seek microbial markers of virulence 
but also spend more effort on identi-
fying the human genetic factors that 
predispose to invasion by patho-
gens. Moreover, common infections 
with low virulence may represent 
the unknown environmental trig-
ger for diseases that are not clearly 
infectious—such as, multiple sclero-
sis, asthma, and acute lymphocytic 
leukemia—when they infect a geno-
type predisposed to the disease.
Diagnostic and Prognostic Signa-
tures in the Host Transcriptome
The host genotype ultimately mani-
fests its function through differences 
in gene transcription or functional 
differences in proteins. Advances in 
analysis of gene expression profiling 
via microarrays, and also in proteom-
ics, not only show how pathogens 
remodel the host’s gene expression 
patterns (Jenner and Young, 2005) 
but also provide a wealth of candi-
date genes for genetic susceptibility 
studies. Some of these changes are 
common to large groups of infection; 
for instance, many viruses stimu-
late interferon response pathways. 
Changes in gene expression profiles 
can also betray the type of pathogen 
present with the potential of identify-
ing the pathogen through host gene 
expression (Huang et al., 2001). 
Thus, gene expression patterns in 
blood could serve as a window into 
the pathogenesis and diagnosis of 
infectious diseases. Whole blood 
and purified peripheral blood mono-
nuclear cells exhibit interpatient 
variation, reflected in the global gene 
expression patterns of the samples 
but nevertheless can be interpreted 
through knowledge of other clinical 
parameters such as differential blood 
counts, temperature, and gender. 
When these are accounted for, the 
remaining gene expression changes 
indicate both general infection and 
disease-specific responses (Griffiths 
et al., 2005; Whitney et al., 2003).
Transcriptional profiles may also 
be expected to aid prognosis and 
responses to treatment as is now the 
case in oncology (Bild et al., 2006). 
For example, some HIV-infected 
patients on antiretroviral therapy do 
not respond with falling viral load 
even when the virus itself shows 
no markers of drug resistance, and 
it may be that host factors deter-
mine nonresponsiveness in these 
cases. Similarly, only a proportion 
of patients with hepatitis C infection 
respond to interferon treatment, and 
transcriptional profiling may indicate 
why this is so. This is an area where 
infectogenomics and pharmacog-
enomics merge.
Combating the Pathogen through 
Host Functional Genomics
Transcriptional profiles specific for 
infected cells also provide insights 
into known pathways of gene regu-lation and reveal new ways of treat-
ing or managing infections (Kellam, 
2006). For example, a study of gene 
expression among B cell lympho-
mas delineated a distinct interaction 
of Kaposi sarcoma associated virus 
(KSHV) from that of EBV. Because 
KSHV-infected lymphoma cells show 
upregulation of the vitamin D recep-
tor pathway, known inhibitors of that 
pathway may be explored therapeu-
tically (Jenner et al., 2003). Similarly, 
cyclo-oxygenase 2 (COX-2) inhibi-
tors were successfully tested for 
reduction of CMV titer after detection 
of upregulation of COX-2 expres-
sion in infected cells. In addition, the 
HIV-1 Nef protein increases choles-
terol biosynthesis, suggesting that 
cholesterol-lowering drugs such as 
statins may have an antiviral effect in 
vivo (del Real et al., 2004).
Thus new roles for known drugs 
are emerging from studies of infec-
togenomics. Such insights could 
provide an increased pharmaceutical 
inventory based on drugs that have 
already undergone extensive toxicity 
and efficacy screening as treatment 
for other diseases (Kellam, 2006).
Conclusions
The functional genomics of the host 
is of crucial importance in analyzing 
host-pathogen interactions. Host 
genetic variation plays a key role in 
determining the outcome of many 
potentially pathogenic infections, 
and the prevalent pathogens have 
influenced the genetic make-up of 
human populations. Infectogenom-
ics can be harnessed to identify 
infectious states, to understand the 
host response, to predict disease 
outcomes, to monitor responses 
to antimicrobial therapies, and to 
indicate promising new types of 
treatment. In addition, we should 
acknowledge that the disease state 
can inform our understanding of 
normality. Just as virology led us to 
oncogenes, tumor suppressor pro-
teins, membrane trafficking path-
ways, and other aspects of molecu-
lar cell biology in the past, so can 
studies of the perturbation of the 
transcriptome by infection open new 
vistas onto “systems” biology today.Cell 124, FebRefeRences
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